1. Home
  2. FUSE vs CMMB Comparison

FUSE vs CMMB Comparison

Compare FUSE & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fusemachines Inc.

FUSE

Fusemachines Inc.

HOLD

Current Price

$0.28

Market Cap

12.5M

Sector

Technology

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

SELL

Current Price

$1.22

Market Cap

10.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
FUSE
CMMB
Founded
2013
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5M
10.9M
IPO Year
2025
2023

Fundamental Metrics

Financial Performance
Metric
FUSE
CMMB
Price
$0.28
$1.22
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $15.00
AVG Volume (30 Days)
★ 61.9K
59.0K
Earning Date
11-03-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
96.38
★ 101.67
EPS
N/A
★ 0.04
Revenue
★ $7,714,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$28.00
Revenue Growth
N/A
★ N/A
52 Week Low
$0.22
$0.92
52 Week High
$3.67
$2.99

Technical Indicators

Market Signals
Indicator
FUSE
CMMB
Relative Strength Index (RSI) 35.08 43.53
Support Level $0.22 $0.99
Resistance Level $0.41 $1.91
Average True Range (ATR) 0.05 0.19
MACD 0.00 0.02
Stochastic Oscillator 21.73 20.74

Price Performance

Historical Comparison
FUSE
CMMB

About FUSE Fusemachines Inc.

Fusemachines Inc is a provider of enterprise AI solutions, offering products such as AI Studio, AI Engines, and AI Agents, along with supporting services across various industries. Its solutions are supported by a talent pool from underserved communities, enabling scalable and high-quality AI delivery while promoting access to AI. The Company serves clients across industries, including healthcare, media, technology, and government, helping address challenges such as improving forecasting accuracy, reducing data entry errors, automating recruitment, and detecting fraud. Its product suite includes AI Studio, AI Engines, and AI Agents, designed to build, deploy, and scale AI solutions, and it operates in Nepal and the United States.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: